Therapeutics / Drugs

For more information on UTMDACC technologies, please contact the Office of Technology Commercialization (713-745-9604).  Please indicate the technology number (MDA#) in your correspondence.

MDA09-066
Peptidomemetic Inhibitors of STat3
Please contact the office for more information on this technology.

MDA09-058
Treatment of Astrocytes -Tumor Cells with Inhibitors of Endothelin Receptors
Please contact the office for more information on this technology.

MDA09-050
Tx-262 a Unique Beta Lactam with Unusual Anti-Cancer Activities
Please contact the office for more information on this technology.

MDA09-049
Near-infrared Light Triggered Drug Release from Hollow Gold Nanospheres (HAuNSs) and HAuNSs-Loaded Microspheres
Please contact the office for more information on this technology.

MDA09-016
Nanoparticle Formulated Glycolipid Antigens of NKT Cells for Immunotherapy of Cancer and Chronic Viral Diseases
Please contact the office for more information on this technology.

MDA08-154
Combination Therapy with Synthetic Triterpenoids and Gemcitabine
US-2009-0048205-A1
WO/2009/023845

MDA08-150
MUC 18-homing ligands enable melanoma targeting in vivo.
Please contact the office for more information on this technology.

MDA08-138
Novel Nanoparticles Containing a natural compound for Cancer Treatment
Please contact the office for more information on this technology.

MDA08-067
Composition and Methods for Treating Lung Cancer
Please contact the office for more information on this technology.

MDA07-106
Gleevec Inhibits the Expression of Narcotic Tolerance and Reverses Established Narcotic Tolerance
WO/2009/048947

MDA07-102
A Theragnostic Approach to Improve Radiochemotherapy Effects - Method of Use
Please contact the office for more information on this technology.

MDA07-074
Mithramycin Inhibits Angiogenesis
US 2008-0274121 A1

MDA07-072
Small Molecule Inhibitors for Immune Modulation
WO 2008/121858

MDA07-063
Nanoparticles for the Delivery of Therapeutic Agents
WO2009/048958

MDA07-053
Method of Cancer Treatment with Naththol Analogues
WO 2008/106248

MDA06-146
Inhibitors of Ephrin Kinase and Hif1alpha and the Design, Synthesis and Uses Thereof
WO 2008/030795

MDA06-143
Inhibitors of c-Met Kinaseand the Design, Synthesis, and Use Thereof
WO 2008/030744

MDA06-113
Small Molecule Modulators of Signaling Protein Redistribution and Destabilization as Therapeutic Agents
WO2008/005954

MDA06-112
Design of Inhibitors to c-Kit Kinase by Structure-Based Drug Design
WO 2008/005877

MDA06-048
Novel e-Kit Inhibitor Based on Protein Wrapping Technology
WO 2008/070350

MDA06-047
High Rate of Sustained Complete Response in Selected Patients with Metastatic Colorectal Cancer with Capecitabine and Celecoxib (XCEL): A Fortuitous Metronomic Regimen
WO2007/103828
US-2009-0156548-A1

MDA06-004
Cromolyn as as Cancer Treatment
US-2008-0214491-A1
US-2009-0062319

MDA05-041
A Phase 1-2, Dose Escalation and Efficacy Study of Oral TAC-101 in Patients with Advanced Hepatocelluar Carcinoma
Please contact the office for more information on this technology.

MDA04-095
An Improved Antiseptic With Penetration Enhancing Formulations and Combination Antiseptic and Topical Agent Formulations
WO 2006/135854
US-2009-0162301

MDA04-008
Locoregional Internal Radionuclide Ablation of Abnormal Tissue in Animals and Humans
US-2007-0217998-A1

MDA03-038
Antimicrobials in Combination with Chelators and Ethanol for the Rapid Eradication of Microorganisms Embedded in Biofilm
US-2005-0013836-A1
WO2004/108091A2

MDA01-036
Adjuvant Chemotherapy of Anaplastic Gliomas with the Combination of Eflornithine, Lomustine, Matulane, and Vincristine
6,653,351
WO03/015763

MDA00-065
Thienopyrimidine Based Inhibitors of pp60c-src
6,503,914
7,285,556
RE39267
WO02/057271

MDA00-002
A Novel MDR-1 Independent Anthracycline in Relapsed/Refractory AML
6,929,802
7,204,996
WO01/32145

MDA99-004
Highly Potent Anthracycline-Based Antitumor Agents
6,437,105
6,680,300
WO00/26223

MDA97-048
Platinum Complexes as Effective Antitumor Agents in Combination with Biochemical Modulation
7,271,161
WO2004/024062

MDA97-046
Chelators in Combination with Biocides: Treatment of Microbially Induced Biofilm and Corrosion
6,267,979
WO/99/10017

MDA96-035
Parenteral Paclitaxel in a Stable Non-Toxic Formulation without Polyoxyethylated Castor Oil and Alcohol
5,877,205
6,107,333
WO/1998/000128

MDA96-033
Parenteral Pimaricin as Treatment of Systemic Infections
6,045,815
7,153,838
7,220,726
WO99/08663

MDA96-029
EDTA and Other Chelators With or Without Antifungal Antimicrobial Agents for the Prevention and Treatment of Fungal Infections
6,165,484
6,509,319
US-2003-0032605-A1
WO99/09997

MDA92-022
M-EDTA Pharmaceutical Preparations and Uses Thereof
5,362,754
5,688,516
WO94/10838

MDA90-014
Anthracycline Analogues Bearing Latent Alkylating Substituents
5,196,522
6,284,737
6,433,150
WO92/07866

MDA88-020
Water Soluble 1,2 - Diaminocyclohexane Platinum (IV) Complexes as Antitumor Agents
5,041,578
5,318,962
5,288,887
5,393,909
5,434,256